Navigation Links
Independent publication supports the profile of CeNeS phase II,compound, CNS 5161

possibility. These properties of CNS 5161, together with its low liability to induce side-effects, are the scientific foundation for our clinical development programme of CNS 5161 as a novel treatment for the major neuropathic pain market. We plan to test CNS 5161 in further Phase II trials in cancer pain and neuropathic pain later this year."

*In vitro and in vivo characterization of [3H]CNS-5161. A use-dependent ligand for the N-methyl-d-aspartate receptor in rat brain. Biegon et al., Synapse, volume 61, pages 577-586, 2007.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About CNS 5161 A range of primary diseases or conditions such as diabetes, cancer, HIV/Aids and shingles, or surgical procedures such as limb amputation can result in nerve damage which leads to a sustained chronic pain. This neuropathic pain is difficult to treat as traditional analgesics do not provide adequate relief for many patients. Drug treatments for neuropathic pain represent a significant area of unmet medical need and a growing market opportunity that is currently valued at over $2 billion globally. Glutamate (particularly NMDA) receptors have been implicated in the induction and maintenance of neuropathic pain and NMDA antagonists may represent a class of drugs for effective relief of neuropathic pain. CNS 5161 is a blocker of the NMDA ion channel and has completed Phase I and more recently Phase IIa proof of c
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
8. CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
11. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
Post Your Comments:
(Date:9/19/2014)... N.J. , Sept. 19, 2014 Merck (NYSE: ... States and Canada , is teaming ... Desafiando La Diabetes: Logra Tus Metas , an educational program encouraging ... blood sugar -- a key treatment goal to help reduce the ... States are at a higher risk for developing type ...
(Date:9/19/2014)... R.I. , Sept. 19, 2014 Larry ... CVS ), will speak before the National Press ... will discuss the company,s recent move to stop selling tobacco ... shape the future of health. "Dramatic changes in ... health care providers and government," Merlo has said. "CVS Health ...
(Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... , , LACHEN, Switzerland and HOBOKEN, N.J., ... m a AG is leading an ... therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, ... from a human cell line, could dramatically impact the treatment of an ...
... , , , ... AMGN ) today announced that in a large, randomized, double-blind, placebo-controlled, ... requiring dialysis), anemia and type-2 diabetes (the T rial to ... T herapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin ...
Cached Medicine Technology:Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 2Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 3Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 4Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 5Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 2Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 3Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 4Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 5Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 6Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 7Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 8
(Date:9/20/2014)... Ticket Down is a reputable ... her 2015 “Honeymoon Tour.” This well-known ticket exchange is ... , In early 2015, fans will have a chance to ... North America. Twenty-one-year-old Ariana Grande will hit the road in ... to 25 cities across the United States and Canada. Grande, ...
(Date:9/20/2014)... The excitement is building up once again for the ... This year the Surry Arts Council will be celebrating its 25th ... who are still fans of the Andy Griffith Show. ... on CBS from 1960 through 1968. The show ranked by ... Mount Airy, North Carolina is where the show was filmed ...
(Date:9/20/2014)... September 20, 2014 Earlier this week, Home ... may have had their credit card information pilfered by hackers, ... a slew of headline articles like this one ... only eye opening numbers. , “Most people tend to ... like it’s a way to score a game,” says Joe ...
(Date:9/20/2014)... 2014 The first federal bellwether trial ... its third week in the U.S. District Court, Northern ... documents indicate that the week opened in the ... a DePuy Orthopaedics vice president, who discussed the clinical ... Pinnacle hip replacement. According to Reuters, the executive stated ...
(Date:9/19/2014)... 2014 Consistent premium price increases ... Vision Insurance industry in recent years; however, costs ... industry margins. From 2009 to 2014, industry revenue ... coverage for routine eye exams and other procedures, ... lens and refractive surgery. According to IBISWorld Industry ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4
... symptoms of grief linger and become increasingly debilitating. This ... and post-traumatic stress disorder (PTSD). // And there ... may bring relief, reports the October issue of the ... symptoms of complicated grief are intrusive thoughts of the ...
... the South Australian Government’s decision to review the types of ... SA Government says it’s concerned that chips, lollies, chocolate and ... vending machines and canteens. ,Dr Haikerwal said many ... ,“Hospitals should make healthy food the easy option,” ...
... staff working the night shift could benefit from a ... research has revealed. // ,In their editorial ... Professor Doug McEvoy and Professor Leon Lack of Flinders ... short periods of shut-eye for medical staff working through ...
... the University of Washington, in Seattle, a group of engineers ... latest creation: a surgical robot// to deploy in far-flung places, ... ,Military groups all over the world have long ... time often decides who lives and who dies. A recent ...
... Children's Research Hospital have discovered that a protein called ABCB6 ... is key to the ability// of red blood cells to ... of cells to extract energy from nutrients. ,The ... outer membrane of the cell’s energy powerhouse called the mitochondria; ...
... the good news: Suicide rates among younger and older Americans ... news: No one really knows why// . ,Those ... the University of South Carolina and released Thursday (Sept. 28) ... Health. ,Dr. Robert McKeown, a professor and associate ...
Cached Medicine News:Health News:Power Naps to Fight Night-shift Fatigue 2Health News:Doc at a Distance 2Health News:ABCB6 Is Key to Production of Heme in Hemoglobin 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 3
Precision near-field imaging combined with the best handling IVUS catheter....
Premium Full Color Digital Ultrasound...
... VH series, it is a ... independent C-arms and image intensifiers, ... for Cardiovascular and Angiography. There ... the examinations for cerebral, cardiac, ...
This catheter is intended for ultrasound examination of coronary intravascular pathology only. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Medicine Products: